Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Fig. 3

Proportion of patients achieving ≥ 50% reduction from baseline in MMD (Full Analysis Set). P-values reported for the dichotomous secondary endpoint (proportion of patients achieving ≥ 50% reduction in MMD) are nominal and should be interpreted with caution. n, number of patients who achieved ≥ 50% reduction in MMD; M, total number of patients in the treatment group with response variable defined. Note: Statistical analysis for the proportion of patients with ≥ 50% reduction from baseline in MMD was done using CMH test adjusting for stratification factor after missing data was imputed (NRI). CI, confidence interval; CMH Cochran–Mantel–Haenszel; MMD monthly migraine day; NRI non-responder imputation; OR, odds ratio

Back to article page